Chronic obstructive pulmonary disease

Deborah Heart and Lung Center Introduces Remote Patient Monitoring for COPD Patients

Tuesday, May 26, 2020 - 12:00pm

BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).

Key Points: 
  • BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).
  • Patients diagnosed with COPD require physician monitoring to prevent the disease from progressing.
  • With the expansion of telemedicine and remote monitoring services prompted by the Coronavirus epidemic, Deborah has instituted a new remote patient monitoring services platform.
  • Called HGE Care the remote monitoring platform is designed for COPD patients who have been discharged from the hospital and are recuperating at home.

Global Ventilator Market Report 2020-2025: Featuring Profiles of Key Players Medtronic, Zoll Medical, Getinge AB, Allied Healthcare Products and Air Liquide

Friday, May 22, 2020 - 8:00pm

DUBLIN, May 22, 2020 /PRNewswire/ -- The "Ventilator Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 22, 2020 /PRNewswire/ -- The "Ventilator Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.
  • The rise in cases of respiratory emergencies and Chronic Obstructive Pulmonary Disease (COPD) are the major factors, which are strengthening the growth of global ventilator market.
  • The "Ventilator Market - Forecasts from 2020 to 2025" report segments the industry as follows:

Global Ventilator Market 2020: Innovation is Key to Meet Surge in Demand from COVID-19 - ResearchAndMarkets.com

Thursday, May 21, 2020 - 10:21am

The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.

Key Points: 
  • The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.
  • The rise in cases of respiratory emergencies and Chronic Obstructive Pulmonary Disease (COPD) are the major factors, which are strengthening the growth of global ventilator market.
  • For example in light of the global pandemic that has gripped our planet and the impact that has permeated every aspect of human, innovation has been key.
  • The "Ventilator Market - Forecasts from 2020 to 2025" report segments the industry as follows:

Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valves, a Revolutionary Treatment Option for Patients with Severe Emphysema/COPD

Monday, May 18, 2020 - 3:04pm

Before Zephyr Valves, patients with advanced disease struggled and were not always good candidates for more invasive surgical procedures.

Key Points: 
  • Before Zephyr Valves, patients with advanced disease struggled and were not always good candidates for more invasive surgical procedures.
  • The HAS reimbursement decision validates that treatment with Zephyr Valves, with appropriate patient selection, represents an effective and safe option for emphysema/COPD patients across France.
  • By providing reimbursement coverage for the Zephyr Valve, emphysema patients in France will now benefit from improved breathing and quality of life.
  • Physicians managing COPD should learn about this treatment option, understand which patients qualify, and refer those patients to a Zephyr trained treatment center.

Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valves, a Revolutionary Treatment Option for Patients With Severe Emphysema/COPD

Monday, May 18, 2020 - 2:17pm

The medical community in France now has a great opportunity to access this option to help patients breathe easier and re-engage with life activities.

Key Points: 
  • The medical community in France now has a great opportunity to access this option to help patients breathe easier and re-engage with life activities.
  • The HAS reimbursement decision validates that treatment with Zephyr Valves, with appropriate patient selection, represents an effective and safe option for emphysema/COPD patients across France.
  • By providing reimbursement coverage for the Zephyr Valve, emphysema patients in France will now benefit from improved breathing and quality of life.
  • Physicians managing COPD should learn about this treatment option, understand which patients qualify, and refer those patients to a Zephyr trained treatment center.

The Global Respiratory Disease Vaccine Market is expected to grow from USD 18,236.13 Million in 2018 to USD 25,236.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.75%

Thursday, May 14, 2020 - 6:30pm

On the basis of Disease Type, the Global Respiratory Disease Vaccine Market is studied across Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Measles, Pertussis, and Pneumonia.

Key Points: 
  • On the basis of Disease Type, the Global Respiratory Disease Vaccine Market is studied across Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Measles, Pertussis, and Pneumonia.
  • On the basis of Vaccine, the Global Respiratory Disease Vaccine Market is studied across DTaP, Haemophilus Influenzae Type B (HIB), MMR, PPSV23, and Respiratory Syncytial Virus (RSV).
  • What are the factors that affect the growth in the Global Respiratory Disease Vaccine Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Respiratory Disease Vaccine Market?

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

Thursday, May 14, 2020 - 7:00am

The response supports Verona Pharma progressing with its planned Phase 3 clinical program, which is expected to start later in 2020.

Key Points: 
  • The response supports Verona Pharma progressing with its planned Phase 3 clinical program, which is expected to start later in 2020.
  • It is planned to be called the ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) program.
  • Based on the FDA response, Verona Pharma is accelerating preparations for the Phase 3 clinical program to start later in 2020.
  • Verona Pharma is currently evaluating three formulations of ensifentrine for the treatment of COPD in Phase 2 clinical trials: nebulized, dry powder inhaler, and pressurized metered-dose inhaler.

ResMed Announces Participation in the Bank of America Merrill Lynch Global Healthcare Conference

Wednesday, May 6, 2020 - 2:00pm

More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .

Key Points: 
  • More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com .
  • The webcast replay will be available approximately one hour after the live webcast ends and will be accessible through September 12, 2020, following the conference.
  • At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives.
  • Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases.

Global Breath Analyzer Markets, 2020-2025 - Rising Demand for Effective Diagnosis of Cancer and Other Diseases is Boosting Growth - ResearchAndMarkets.com

Tuesday, May 5, 2020 - 2:42pm

The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global breath analyzer market is currently witnessing robust growth.
  • Furthermore, the rising demand for effective diagnosis of cancer and other diseases, including asthma and chronic obstructive pulmonary disease (COPD), is also providing a boost to the market growth.
  • How has the global breath analyzer market performed so far and how will it perform in the coming years?

Pulmonx Secures $66M in Financing to Support Commercial Acceleration of the Zephyr Valve System, a Minimally-Invasive Treatment for Severe Emphysema

Tuesday, May 5, 2020 - 2:10pm

Proceeds from this financing will ensure that Pulmonx is well-capitalized to support the continued global commercial expansion of the Zephyr Valve System, the first FDA-approved minimally-invasive treatment option for severe emphysema, a form of COPD.

Key Points: 
  • Proceeds from this financing will ensure that Pulmonx is well-capitalized to support the continued global commercial expansion of the Zephyr Valve System, the first FDA-approved minimally-invasive treatment option for severe emphysema, a form of COPD.
  • The combination of Pulmonx Zephyr Valve System, patient assessment tools, established reimbursement programs, and global commercial footprint positions it as the world leader in interventional COPD procedures.
  • It is estimated that more than 1.2M severe emphysema patients in the US, Europe and Japan are candidates for the Zephyr Valve treatment.
  • FDA granted the Zephyr Valve a breakthrough device designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve.